AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ... New England Journal of Medicine 371 (11), 1028-1038, 2014 | 2838 | 2014 |
Hedgehog signalling in prostate regeneration, neoplasia and metastasis SS Karhadkar, G Steven Bova, N Abdallah, S Dhara, D Gardner, A Maitra, ... Nature 431 (7009), 707-712, 2004 | 1384 | 2004 |
KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11. 2 JT Dong, PW Lamb, CW Rinker-Schaeffer, J Vukanovic, T Ichikawa, ... Science 268 (5212), 884-886, 1995 | 1268 | 1995 |
Activation of programmed cell death in the rat ventral prostate after castration N Kyprianou, JT Isaacs Endocrinology 122 (2), 552-562, 1988 | 911 | 1988 |
Etiology and disease process of benign prostatic hyperplasia JT Isaacs, DS Coffey The Prostate 15 (S2), 33-50, 1989 | 876 | 1989 |
A history of prostate cancer treatment SR Denmeade, JT Isaacs Nature Reviews Cancer 2 (5), 389-396, 2002 | 781 | 2002 |
Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation N Kyprianou, HF English, JT Isaacs Cancer research 50 (12), 3748-3753, 1990 | 669 | 1990 |
Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene B Levine, Q Huang, JT Isaacs, JC Reed, DE Griffin, JM Hardwick Nature 361 (6414), 739-742, 1993 | 644 | 1993 |
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer SR Denmeade, XS Lin, JT Isaacs The prostate 28 (4), 251-265, 1996 | 600 | 1996 |
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation N Kyprianou, HF English, NE Davidson, JT Isaacs Cancer research 51 (1), 162-166, 1991 | 559 | 1991 |
Adaptation versus Selection as the Mechanism Responsible for the Relapse of Prostatic Cancer to Androgen Ablation Therapy as Studied in the Dunning R-3327 … JT Isaacs, DS Coffey Cancer research 41 (12_Part_1), 5070-5074, 1981 | 538 | 1981 |
Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death N Kyprianou, JT Isaacs Molecular Endocrinology 3 (10), 1515-1522, 1989 | 534 | 1989 |
Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers JT Isaacs, WB Isaacs, WFJ Feitz, J Scheres The Prostate 9 (3), 261-281, 1986 | 531 | 1986 |
Antagonistic effect of androgen on prostatic cell death JT Isaacs The Prostate 5 (5), 545-557, 1984 | 526 | 1984 |
Implication of cell kinetic changes during the progression of human prostatic cancer. RR Berges, J Vukanovic, JI Epstein, M CarMichel, L Cisek, DE Johnson, ... Clinical cancer research: an official journal of the American Association …, 1995 | 499 | 1995 |
Down-Regulation of the KAI1 Metastasis Suppressor Gene during the Progression of Human Prostatic Cancer Infrequently Involves Gene Mutation or Allelic Loss JT Dong, H Suzuki, SS Pin, GS Bova, JA Schalken, WB Isaacs, JC Barrett, ... Cancer Research 56 (19), 4387-4390, 1996 | 410 | 1996 |
The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin Y Furuya, P Lundmo, AD Short, DL Gill, JT Isaacs Cancer research 54 (23), 6167-6175, 1994 | 400 | 1994 |
The biology of hormone refractory prostate cancer: Why does it develop? JT Isaacs Urologic Clinics of North America 26 (2), 263-273, 1999 | 399 | 1999 |
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer SR Denmeade, CM Jakobsen, S Janssen, SR Khan, ES Garrett, H Lilja, ... Journal of the National Cancer Institute 95 (13), 990-1000, 2003 | 356 | 2003 |
Clinical evidence for and implications of the multistep development of prostate cancer HB Carter, S Piantadosi, JT Isaacs The Journal of urology 143 (4), 742-746, 1990 | 356 | 1990 |